Silo Pharma Inc
SILO
查看详细走势图
0.385USD
+0.010+2.69%
收盘 12/24, 13:00（美东）报价延迟15分钟
4.03M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+2.69%
5天
-3.92%
1月
-9.58%
6月
-37.63%
今年开始到现在
-56.71%
1年
-59.81%
查看详细走势图
TradingKey Silo Pharma Inc股票评分
单位: USD 更新时间: 2025-12-24操作建议
Silo Pharma Inc当前公司基本面数据相对非常健康，增长潜力较大。当前估值合理，在药品行业排名119/158位。机构持股占比非常高，中期看，股价处于下降通道。近一个月，市场表现较差，但基本面评分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Silo Pharma Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
0
位分析师
--
评级
0.000
目标均价
0.00%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Silo Pharma Inc亮点
亮点风险
Silo Pharma, Inc. is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company. The Company’s therapeutic focus is on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The Company’s portfolio includes programs, such as for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer’s disease and multiple sclerosis. Its lead product candidate, SPC-15, is designed as a novel serotonin 4 (5-HT4) receptor agonist that utilizes biomarkers for treatment of stress-induced psychiatric disorders such as PTSD and anxiety disorders. SPC-14 targets glutamate receptor NDMAR and serotonin 5-HT4 to address cognitive and neuropsychiatric symptoms in Alzheimer’s disease. SPU-16 is a candidate targeting central nervous system (CNS) disorders, with an initial indication for multiple sclerosis.
业绩增长期
公司处于发展阶段，最新年度总收入72.10K美元
估值高估
公司最新PE估值-0.42，处于3年历史高位
机构加仓
最新机构持股587.46K股，环比增加22.80%
先锋集团持仓
明星投资者先锋集团持仓，最新持仓市值16.33K
活跃度降低
近期活跃度降低，过去20天平均换手率-0.79
Silo Pharma Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Silo Pharma Inc简介
Silo Pharma, Inc. is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company. The Company’s therapeutic focus is on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The Company’s portfolio includes programs, such as for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer’s disease and multiple sclerosis. Its lead product candidate, SPC-15, is designed as a novel serotonin 4 (5-HT4) receptor agonist that utilizes biomarkers for treatment of stress-induced psychiatric disorders such as PTSD and anxiety disorders. SPC-14 targets glutamate receptor NDMAR and serotonin 5-HT4 to address cognitive and neuropsychiatric symptoms in Alzheimer’s disease. SPU-16 is a candidate targeting central nervous system (CNS) disorders, with an initial indication for multiple sclerosis.
公司代码SILO
公司Silo Pharma Inc
CEOWeisblum (Eric)
网址https://silopharma.com/
常见问题
Silo Pharma Inc(SILO)的当前股价是多少？
Silo Pharma Inc(SILO)的当前股价是 0.385。
Silo Pharma Inc的股票代码是什么？
Silo Pharma Inc的股票代码是SILO。
Silo Pharma Inc股票的52周最高点是多少？
Silo Pharma Inc股票的52周最高点是3.370。
Silo Pharma Inc股票的52周最低点是多少？
Silo Pharma Inc股票的52周最低点是0.360。
Silo Pharma Inc的市值是多少？
Silo Pharma Inc的市值是4.03M。
Silo Pharma Inc的净利润是多少？
Silo Pharma Inc的净利润为-4.39M。
现在Silo Pharma Inc(SILO)的股票是买入、持有还是卖出？
根据分析师评级，Silo Pharma Inc(SILO)的总体评级为--，目标价格为--。
Silo Pharma Inc(SILO)股票的每股收益（EPS TTM）是多少
Silo Pharma Inc(SILO)股票的每股收益（EPS TTM）是-0.911。
相关品种
